Products - Thyroid cancer | Topic | NICE

Showing 10 products

Date | Title

Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine (TA928)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2023
Cabozantinib for treating medullary thyroid cancer (TA516)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2018
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Pralsetinib for thyroid cancer [ID4018]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 November 2021
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Thyroid cancer: assessment and management (NG230)
Product type:
Guidance
Programme:
NICE guideline
Published:
19 December 2022
Vandetanib for treating medullary thyroid cancer (TA550)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2018